ANXA5 and acute myeloid leukemia: Then we tested the antileukemic effects of LY2603618 and ABT-199 in two primary patient samples which were relatively resistance to ABT-199 (AML#31 ABT-199 IC50 was 1 μM and AML#38 ABT-199 IC50 was 5 μM, as determined by MTT assays) by Annexin V/PI staining and flow cytometry analyses (patient characteristics are presented in Table 1).